Zobrazeno 1 - 10
of 1 403
pro vyhledávání: '"A. A. Shumilova"'
Autor:
T. M. Reshetnyak, F. A. Cheldieva, N. M. Kosheleva, A. A. Shumilova, L. M. Blank, N. V. Seredavkina
Publikováno v:
Научно-практическая ревматология, Vol 62, Iss 3, Pp 325-330 (2024)
Obstetric pathology (pregnancy loss at different gestational ages; premature delivery of morphologically normal foetus due to pre-/eclampsia or placental insufficiency), along with thrombotic complications are the main clinical manifestations of anti
Externí odkaz:
https://doaj.org/article/fb3c934fe22043f8bd437d4f4bf1222d
Autor:
T. M. Reshetnyak, E. A. Aseeva, A. A. Shumilova, N. Yu. Nikishina, S. Yu. Shkireeva, A. M. Lila
Publikováno v:
Современная ревматология, Vol 17, Iss 6, Pp 14-21 (2023)
In recent years the use of monoclonal antibodies that block activity of type I interferon (IFN) or its receptors has become the new approach in the pharmacotherapy of systemic lupus erythematosus (SLE).Objective: to characterize patients with SLE tre
Externí odkaz:
https://doaj.org/article/8a966313917d40ac873741cfc5d7fe07
Autor:
T. M. Reshetnyak, E. A. Aseeva, A. A. Shumilova, N. Yu. Nikishina, S. I. Glukhova, S. Yu. Shkireeva, A. M. Lila
Publikováno v:
Современная ревматология, Vol 18, Iss 2 (2024)
Objective: to evaluate the efficacy and safety of the type I interferon (IFN) receptor inhibitor anifrolumab (AFM, Safnelo®) in patients with systemic lupus erythematosus (SLE) in real-life clinical practice over an observation period of 6 months.Ma
Externí odkaz:
https://doaj.org/article/38fb602ba54c47b28b5841d42f364be9
Publikováno v:
Современная ревматология, Vol 17, Iss 5, Pp 15-21 (2023)
To date, the management of patients with antiphospholipid syndrome (APS) with ineffectiveness and/or intolerance to vitamin K antagonists and direct oral anticoagulants remains controversial. One of the treatment strategies is the administration of l
Externí odkaz:
https://doaj.org/article/09e4ca76caef4b979b8a329aa5f453d5
Autor:
A. A. Shumilova, F. A. Cheldieva, K. S. Nurbaeva, T. A. Lisitsyna, L. M. Carter, E. M. Vital, T. M. Reshetnyak
Publikováno v:
Современная ревматология, Vol 17, Iss 5, Pp 107-111 (2023)
Assessment of systemic lupus erythematosus (SLE) activity is important to determine the efficacy of treatment and to decide on further therapy. Russian-language versions of activity indices are needed to meet the needs of Russian-speaking patients an
Externí odkaz:
https://doaj.org/article/2546513de6c54675b0cb8b477063728e
Autor:
F. A. Cheldieva, T. M. Reshetnyak, A. A. Shumilova, K. S. Nurbaeva, M. V. Cherkasova, A. M. Lila, E. L. Nasonov
Publikováno v:
Научно-практическая ревматология, Vol 60, Iss 5, Pp 546-553 (2022)
Introduction. The Global Antiphospholipid Syndrome Score (GAPSS) is a tool proposed to quantify the risk of clinical manifestations associated with antiphospholipid antibodies (aPL) and certain cardiovascular risk factors.Objective. To validate GAPSS
Externí odkaz:
https://doaj.org/article/34f8ead4e6d14878ab149c2a524fc281
Publikováno v:
Современная ревматология, Vol 16, Iss 4, Pp 7-14 (2022)
Skin lesions in systemic lupus erythematosus (SLE) are not just a cosmetic defect, accompanied by a deterioration in the quality of life and psychological discomfort, but, possibly, the first sign of a systemic course of disease. Systemic involvement
Externí odkaz:
https://doaj.org/article/b470948d6b9e4dada22f532696835ff9
Publikováno v:
Современная ревматология, Vol 16, Iss 3, Pp 7-13 (2022)
Skin and mucous membranes lesions in systemic lupus erythematosus (SLE) significantly impair the quality of life of patients, although they are not a formidable manifestation of the disease. Skin manifestations of SLE can occur both at the onset and
Externí odkaz:
https://doaj.org/article/71c0f5dc55f747caa5d8369b5d12939d
Autor:
F. A. Cheldieva, T. M. Reshetnyak, A. A. Shumilova, K. S. Nurbaeva, M. V. Cherkasova, E. Yu. Samarkina, A. M. Lila
Publikováno v:
Современная ревматология, Vol 17, Iss 1 (2023)
Stratification of patients into groups of high and low risk of adverse outcome is necessary for timely and early prevention of the disease, as well as the selection of adequate therapy.Objective: to validate the global risk scale for the development
Externí odkaz:
https://doaj.org/article/341d07bf15fd4fd4bb266975cd6e8bdc
Publikováno v:
Современная ревматология, Vol 15, Iss 4, Pp 87-93 (2021)
We present two clinical cases: the first patient had combination of antiphospholipid syndrome (APS) and melanoma, and the second – systemic lupus erythematosus (SLE) and APS, melanoma, infiltrative tuberculosis and Herpes zoster. Managing patients
Externí odkaz:
https://doaj.org/article/278de196a0d24a5d9310c8c6ea0f61b4